Method and compositions for producing disulfide-linked trimeric TNF family of cytokines and their use
View Patent ↗Compositions of TNF family of cytokines in covalently linked trimeric forms are disclosed. The resulting fusion proteins are secreted as disulfide bond-linked homotrimers, which are more stable in structure and therapeutically more efficacious than their native counterparts.
1. A method for treating cancer in a mammal, comprising the step of administering to said mammal a therapeutically effective amount of a disulfide bond-linked trimeric TRAIL fusion proteins with an amino acid sequence composition identified by one of SEQ. ID NO. 1 or SEQ. ID NO. 2.
2. The method of claim 1 , wherein the cancer is gastronintestinal cancer.
3. The method of claim 1 , wherein the cancer is colorectal cancer.
4. The method of claim 1 , wherein the cancer is lung cancer.
5. The method of claim 1 , wherein the cancer is pancreatic cancer.
6. The method of claim 1 , wherein the cancer is ovarian cancer.
7. The method of claim 1 , wherein the cancer is a malignant ascites.
8. The method of claim 1 , wherein the cancer is peritoneal carcinomatosis.
9. The method of claim 1 , wherein the disulfide bond-linked trimeric fusion protein is administered via intravenous injection.
10. The method of claim 1 , wherein the disulfide bond-linked trimeric fusion protein is administered via intraperitoneal infusion.
11. The method of claim 1 , wherein the disulfide bond-linked trimeric fusion protein is administered via subcutaneous injection.
12. The method of claim 1 , wherein the disulfide bond-linked trimeric fusion protein is administered in a series of doses separated by intervals of days or weeks.
13. The method of claim 1 , wherein the disulfide bond-linked trimeric fusion protein is administered in combination with chemotherapy.
14. The method of claim 1 , wherein the disulfide bond-linked trimeric fusion protein is administered in combination with a Ras inhibitor.